Clinical trial
Antipsychotic Polypharmacy in Schizophrenia
NCT00493233 · Centre for Addiction and Mental Health, Other · Completed
Key facts
| NCT number | NCT00493233 |
|---|---|
| Title | Antipsychotic Polypharmacy in Schizophrenia |
| Official title | Antipsychotic Polypharmacy in Schizophrenia |
| Lead sponsor | Centre for Addiction and Mental Health, Other |
| Collaborators | Canadian Psychiatric Research Foundation |
| Status | Completed |
| Study type | Interventional |
| Conditions | Schizophrenia |
| Intervention type | Drug |
| Interventions | 2 antipsychotic medications (combinations of olanzapine, risperidone, clozapine, seroquel, haldol, perphenazine), main antipsychotic medication and placebo |
| Enrollment | 100 |
| Start date | Nov 1, 2006 |
| Primary completion | Dec 1, 2008 |
| First posted | Jun 28, 2007 |
| Last update posted | May 19, 2009 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: